homehealthcare NewsIndia's first intranasal COVID vaccine by Bharat Biotech gets DCGI approval

India's first intranasal COVID vaccine by Bharat Biotech gets DCGI approval

Last week, the Subject Expert Committee (SEC) had recommended Emergency Use Authorization (EUA) for Bharat Biotech's intranasal COVID-19 vaccine candidate BBV-154, sources said.

Profile image

By CNBCTV18.com Sept 6, 2022 3:39:01 PM IST (Updated)

Listen to the Article(6 Minutes)
2 Min Read
India's first intranasal COVID vaccine by Bharat Biotech gets DCGI approval
Bharat Biotech's intranasal COVID-19 vaccine candidate has been approved by the Drugs Controller General of India (DCGI), Union Health Minister Mansukh Mandaviya said on Tuesday. This is India's first intra-nasal COVID-19 vaccine Which will be used for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.

The DCGI had earlier given its nod to conduct clinical trials for BBIL's (Bharat Biotech International Limited) intranasal vaccine as a booster dose. The drug regulator had also permitted the firm to conduct a phase-3 clinical trial to compare the immunogenicity and safety of BBV-154 (intranasal) with Covaxin.
Last week, the Subject Expert Committee (SEC) recommended Emergency Use Authorization (EUA) for Bharat Biotech's intranasal COVID-19 vaccine, sources said.
Krishna Ella, Chairman and Managing Director of the company, had said earlier that there was no single instance of side effect or adverse reaction reported so far.
Benefits of COVID-19 nasal vaccine
Speaking about the benefit of nasal injection, Ella was earlier quoted by news agency PTI as saying that any injectable vaccine only protects the lower level (of the body). That's why people vaccinated with injectable vaccines may still get RT-PCR positive, whereas the nasal jab protects the whole body. Bharat Biotech also claimed that the "intranasal vaccine stimulates a broad immune response."
As mentioned by Bharat Biotech, the nasal vaccine is:
  • Likely to block both infection and transmission of COVID-19
  • Non-invasive and needle-free
  • Easy to administer as it does not require trained healthcare workers
  • Eliminates needle-associated risks (injuries and infections)
  • High compliance — ideally suits children and adults
  • Scalable manufacturing — able to meet global demand
  • Most Read

    Share Market Live

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CurrencyPriceChange%Change